🔎 Trials Near Me

Akèy › Kansè ovè › Washington › Seattle

Etid klinik pou Kansè ovè nan Seattle, WA

30 etid pou Kansè ovè ap chèche patisipan nan sit nan ak bò kote Seattle (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Ap rekriteFaz 2
  • Swedish Medical Center-First Hill, Seattle
Tout laj · Tout sèks · Mizajou Oct 2, 2026 · NCT05564377

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Ap rekriteFaz 1/2
  • University of Washington, Fred Hutchinson Cancer Center, Seattle
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Ap rekriteEtid obsèvasyon
  • Fred Hutchinson Cancer Center, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT04981119

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

Ap rekriteFaz 1/2
  • Seattle Cancer Care Alliance at South Lake Union - G3630, Seattle
Laj 18 ak plis · Fanm · Mizajou Sep 24, 2026 · NCT04590326

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

Ap rekriteFaz 2
  • Virginia Mason Hospital and Medical Center /ID# 277259, Seattle
Laj 18 ak plis · Fanm · Mizajou Sep 22, 2026 · NCT07059845

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Ap rekriteFaz 3
  • Swedish Medical Center, Seattle
  • Fred Hutchinson Cancer Center, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07213804

IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence

Ap rekriteFaz 2
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Laj 18 ak plis · Fanm · Mizajou Sep 21, 2026 · NCT07495124

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Ap rekriteFaz 1
  • University of Washington Fred Hutchinson, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05983432

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Ap rekriteFaz 3
  • Virginia Mason Medical Center, Seattle
  • Fred Hutchinson Cancer Center, Seattle
Laj 18 ak plis · Fanm · Mizajou Sep 15, 2026 · NCT07214779

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Ap rekriteFaz 2
  • Swedish Cancer Institute, Seattle
Laj 18 ak plis · Fanm · Mizajou Sep 14, 2026 · NCT06787612

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Ap rekrite
  • Swedish Medical Center-Ballard Campus, Seattle
  • Fred Hutchinson Cancer Center, Seattle
  • Swedish Medical Center-Cherry Hill, Seattle
  • ak 3 plis
Laj 35 a 50 · Fanm · Mizajou Aug 7, 2026 · NCT04251052

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Ap rekriteFaz 3
  • Swedish Medical Center-Ballard Campus, Seattle
  • Fred Hutchinson Cancer Center, Seattle
  • Swedish Medical Center-Cherry Hill, Seattle
  • ak 4 plis
Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT06580314

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

Ap rekriteFaz 1
  • Fred Hutchinson Cancer Center, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT07444814

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Ap rekriteFaz 1/2
  • Swedish Cancer Institute, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT05579366

Clinical Pre-screening Protocol for Ovarian Cancer

Ap rekriteEtid obsèvasyon
  • Swedish Center for Research and Innovation, Seattle
Laj 18 ak plis · Fanm · Mizajou Jul 30, 2026 · NCT03877796

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Ap rekriteFaz 2/3
  • University of Washington - Seattle Cancer Care Alliance, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Jul 28, 2026 · NCT06161025

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Ap rekriteFaz 2
  • University of Washington School of Medicine, Seattle
Laj 8 ak plis · Tout sèks · Mizajou Jul 27, 2026 · NCT05503797

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Ap rekriteFaz 1
  • Swedish Cancer Institute, Seattle
  • Swedish Medical Center, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Jul 6, 2026 · NCT04389632

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

Ap rekriteFaz 1/2
  • Fred Hutchinson Cancer Center, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT05377996

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Ap rekriteFaz 1/2
  • Fred Hutchinson Cancer Center, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Jun 23, 2026 · NCT06993844

Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians

Ap rekriteVolontè an sante akeyi
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Jun 17, 2026 · NCT07282158

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Ap rekriteFaz 1/2
  • Fred Hutchinson Cancer Center, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Jun 12, 2026 · NCT06051695

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Ap rekriteFaz 1/2
  • Fred Hutchinson Cancer Center, Seattle
Laj 18 ak plis · Tout sèks · Mizajou May 13, 2026 · NCT03686124

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

Ap rekriteEtid obsèvasyon
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Tout laj · Tout sèks · Mizajou Apr 17, 2026 · NCT06295965

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

Ap rekrite
  • University of Washington, Seattle
Laj 25 a 50 · Fanm · Mizajou Apr 6, 2026 · NCT04294927

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Ap rekriteFaz 1/2
  • Fred Hutchinson Cancer Center, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Mar 27, 2026 · NCT06395519

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Ap rekriteFaz 1
  • Fred Hutchinson Cancer Center, Seattle
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT06778863

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Ap rekriteEtid obsèvasyon
  • Massive Bio SYNERGY-AI site, Seattle
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774

Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer

Ap rekriteEtid obsèvasyon
  • The Swedish Hospital, Seattle
Laj 30 ak plis · Fanm · Mizajou Sep 16, 2025 · NCT04794322

Etid Kansè ovè nan lòt vil

Lòt etid nan Seattle

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.